NCT04579224 2026-03-19
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
7 trialsNCT06524544 2026-03-18
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT02581982 2023-01-10
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT03464734 2022-11-30
Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT04730219 2022-11-30
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT03051373 2021-08-09
Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract
Chinese PLA General Hospital
Phase 2 Completed